Artificial nasolacrimal duct capable of achieving self-expanding fixation

A nasolacrimal duct and self-expanding technology, which is applied in the human tubular structure device, medical science, prosthesis, etc., can solve the problems of high incidence of shedding, poor biocompatibility, and impossibility of permanent placement, so that it is not easy to fall off , good mechanical properties, easy to operate

Active Publication Date: 2018-03-13
GUANGZHOU SUN SHING BIOTECH CO LTD
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The existing artificial nasolacrimal duct stents are mainly hollow tubes obtained from materials such as nickel-titanium metal, glass, medical silicone rubber, and polyurethane. These materials have relatively poor biocompatibility and cannot be permanently placed. Three months later, a second operation was performed to remove the stent
This often causes secondary damage, leading to reactions such as bleeding and inflammation, and then granulation hyperplasia and other phenomena, resulting in re-occlusion of the lacrimal duct
In addition, these stents are usually fixed by using the end size larger than the physiological size of the lacrimal duct, the fixation effect is poor, and the incidence of shedding is high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Artificial nasolacrimal duct capable of achieving self-expanding fixation
  • Artificial nasolacrimal duct capable of achieving self-expanding fixation
  • Artificial nasolacrimal duct capable of achieving self-expanding fixation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] An embodiment of the artificial nasolacrimal duct of the present invention comprises the following preparation raw materials in parts by weight: 40 parts of hydroxyethyl methacrylate, 20 parts of crosslinking agent, 40 parts of water, 5 parts of thermal initiator and 10 parts of catalyst;

[0036] Wherein, the crosslinking agent is polyethylene glycol diacrylate, the thermal initiator is azobisisobutyronitrile, and the catalyst is N,N,N',N'-tetramethylethylenediamine.

[0037] A kind of artificial nasolacrimal duct prepared by adopting the preparation raw materials of artificial nasolacrimal duct described in the present embodiment, the preparation method of described artificial nasolacrimal duct comprises the following steps:

[0038] (1), mix hydroxyethyl methacrylate, cross-linking agent, water, initiator and catalyst evenly, inject artificial nasolacrimal duct mold;

[0039] (2), the artificial nasolacrimal duct mold containing artificial nasolacrimal duct preparati...

Embodiment 2

[0043] An embodiment of the artificial nasolacrimal duct of the present invention, the difference between the artificial nasolacrimal duct described in this embodiment and embodiment 1 is that the ratio of the thermal initiator and the catalyst is different, the artificial nasolacrimal duct described in this embodiment The preparation raw materials comprising the following parts by weight: 40 parts of hydroxyethyl methacrylate, 20 parts of crosslinking agent, 40 parts of water, 5 parts of thermal initiator and 5 parts of catalyst;

[0044] Wherein, the crosslinking agent is polyethylene glycol diacrylate, the thermal initiator is azobisisobutyronitrile, and the catalyst is N,N,N',N'-tetramethylethylenediamine.

[0045] The preparation method of the artificial nasolacrimal duct described in this example is the same as that in Example 1.

[0046] The size of the artificial nasolacrimal duct described in this embodiment is the same as that of Example 1 before use

Embodiment 3

[0048]An embodiment of the artificial nasolacrimal duct of the present invention, the difference between the artificial nasolacrimal duct described in this embodiment and embodiment 1 is that the ratio of the thermal initiator and the catalyst is different, the artificial nasolacrimal duct described in this embodiment Contains the following preparation raw materials in parts by weight: 40 parts of hydroxyethyl methacrylate, 20 parts of crosslinking agent, 40 parts of water, 5 parts of thermal initiator and 15 parts of catalyst;

[0049] Wherein, the crosslinking agent is polyethylene glycol diacrylate, the thermal initiator is azobisisobutyronitrile, and the catalyst is N,N,N',N'-tetramethylethylenediamine.

[0050] The preparation method of the artificial nasolacrimal duct described in this example is the same as that in Example 1.

[0051] The size of the artificial nasolacrimal duct described in this embodiment is the same as that of Example 1 before use

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
Login to view more

Abstract

The invention discloses an artificial nasolacrimal duct capable of achieving self-expanding fixation. The artificial nasolacrimal duct is of a hollow tubular structure. The inner diameter of the hollow tubular structure is 0.5-1.5 mm, and the outer diameter of the hollow tubular structure is 0.6-4.0 mm: the artificial nasolacrimal duct is made of water absorbent and expansible materials. The artificial nasolacrimal duct is simple in structure, and does not need to be set into a structure with the end size larger than the physiological size of the lacrimal passage so as to achieve the purpose of fixation, the fixation effect is good, and the duct is not easy to fall off after absorbing water and expanding.

Description

technical field [0001] The invention relates to an artificial nasolacrimal duct, in particular to a self-expanding and fixed artificial nasolacrimal duct. Background technique [0002] Epiphora is a common and relatively common eye disease. It is a frequently-occurring disease caused by tear fluid stagnation in the lacrimal sac due to stenosis or blockage of the nasolacrimal duct. Patients with this disease will cry for a long time, which seriously affects the quality of life of the patient. Artificial nasolacrimal duct implantation is a minimally invasive treatment for such diseases. The existing artificial nasolacrimal duct stents are mainly hollow tubes made of materials such as nickel-titanium metal, glass, medical silicone rubber, and polyurethane. These materials have relatively poor biocompatibility and cannot be permanently placed. Three months later, a second operation was performed to remove the stent. This often causes secondary damage, leading to reactions such...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61F2/04A61L27/16A61L27/20A61L27/24A61L27/50A61L27/52
CPCA61F2/04A61F2210/0061A61L27/16A61L27/20A61L27/24A61L27/50A61L27/52A61L2430/22C08L33/10C08L5/08C08L5/04
Inventor 李锐聪杨习锋曾晨光郭少成
Owner GUANGZHOU SUN SHING BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap